CSDE1 and pancreatic adenocarcinoma: CSDE1 has been proposed as a predictive marker for anti-PD1 immunotherapy response in melanoma and as a prognostic biomarker helping to guide adjuvant treatment decisions in resectable pancreatic adenocarcinoma [20,22].